Given that the role of mutant p53 in the progression of osteosarcoma in vivo has not been sufficiently analyzed, we reason that it remains to be elucidated whether mutant p53 is a suitable therapeutic target for osteosarcoma. This evidence concerns the gene TP53 and osteosarcoma.